EXHIBIT 99.1
| Press Release |  |
| www.shire.com |
Result of the 2018 Annual General Meeting
April 24, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that, at its Annual General Meeting held at Block 3, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the Notice of Meeting were decided by poll vote. The results of the poll are as follows:
| Resolutions | For (including discretionary votes) | % | Against | % | Votes cast as a % of relevant shares in issue | Withheld |
| Ordinary Resolutions | ||||||
| 1. To receive the Company’s Annual Report and Accounts for the year ended December 31, 2017. | 688,563,376 | 98.10% | 13,300,687 | 1.90% | 76.93 | 1,346,969 |
| 2. To approve the Directors’ Remuneration Report. | 625,712,659 | 89.13% | 76,327,709 | 10.87% | 76.95 | 1,170,664 |
| 3. To approve the Directors’ Remuneration Policy | 626,537,622 | 89.40% | 74,305,019 | 10.60% | 76.82 | 2,368,391 |
| 4. To re-elect Olivier Bohuon as a Director. | 681,535,745 | 97.43% | 17,973,289 | 2.57% | 76.68 | 3,701,998 |
| 5. To re-elect Ian Clark as a Director. | 691,840,940 | 98.70% | 9,077,475 | 1.30% | 76.83 | 2,292,617 |
| 6. To elect Thomas Dittrich as a Director. | 692,765,004 | 98.84% | 8,143,588 | 1.16% | 76.83 | 2,302,440 |
| 7. To re-elect Gail Fosler as a Director. | 694,283,921 | 99.06% | 6,592,087 | 0.94% | 76.83 | 2,335,024 |
| 8. To re-elect Steven Gillis as a Director. | 668,544,846 | 95.38% | 32,364,118 | 4.62% | 76.83 | 2,302,068 |
| 9. To re-elect David Ginsburg as a Director. | 694,272,085 | 99.05% | 6,637,682 | 0.95% | 76.83 | 2,301,265 |
| 10. To re-elect Susan Kilsby as a Director. | 681,350,666 | 97.36% | 18,487,459 | 2.64% | 76.71 | 3,372,907 |
| 11. To re-elect Sara Mathew as a Director. | 693,737,656 | 98.98% | 7,136,497 | 1.02% | 76.83 | 2,336,879 |
| 12. To re-elect Flemming Ornskov as a Director. | 695,545,113 | 99.23% | 5,376,245 | 0.77% | 76.83 | 2,289,674 |
13. To re-elect Albert Stroucken as a Director. | 689,997,905 | 98.45% | 10,873,689 | 1.55% | 76.83 | 2,339,438 |
| 14. To re-appoint Deloitte LLP as the Company’s Auditor. | 686,450,290 | 97.93% | 14,476,512 | 2.07% | 76.83 | 2,284,230 |
| 15. To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor. | 691,874,604 | 98.54% | 10,247,132 | 1.46% | 76.96 | 1,089,296 |
| 16. To authorize the allotment of shares. | 629,316,219 | 89.61% | 72,937,171 | 10.39% | 76.98 | 957,642 |
| Special Resolutions | ||||||
| 17. To authorize the general disapplication of pre-emption rights. | 693,512,217 | 99.38% | 4,346,569 | 0.62% | 76.49 | 5,352,246 |
| 18. To authorize the specific disapplication of pre-emption rights. | 669,732,867 | 95.97% | 28,111,669 | 4.03% | 76.49 | 5,366,496 |
| 19. To authorize purchases of own shares. | 692,728,090 | 98.67% | 9,365,000 | 1.33% | 76.96 | 1,117,942 |
| 20. To approve the notice period for general meetings. | 662,122,671 | 94.47% | 38,782,050 | 5.53% | 76.83 | 2,306,311 |
As at the record date, April 22, 2018, the Company had 912,293,361 Ordinary Shares of 5 pence each in issue (excluding shares held in treasury). Shareholders are entitled to one vote per share. A vote “withheld” is not a vote in law and is not counted in the calculation of the proportion of votes validly cast.
In accordance with Listing Rule 9.6.2R, copies of the relevant resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at:www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 795 432 359 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Robert Coates | rcoates@shire.com | +44 203 549 0874 |
| Media | ||
| Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.
www.shire.com